triple G agonist

News

Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.

Oncology

Dr Peter Sasieni, co-investigator for the NHS Galleri trial, discusses advances in population-level blood screening for early cancer detection.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.